Synaptogenix is a biotechnology business based in the US. Synaptogenix shares (SNPX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.42 – an increase of 4.09% over the previous week. Synaptogenix employs 4 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.42 |
|---|---|
| 52-week range | $1.84 - $5.38 |
| 50-day moving average | $2.55 |
| 200-day moving average | $3.12 |
| Wall St. target price | $14.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-10.99 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.46 from 2025-05-01
| 1 week (2025-04-25) | 5.81% |
|---|---|
| 1 month (2025-04-03) | 8.37% |
| 3 months (2025-02-03) | -14.88% |
| 6 months (2024-11-01) | -16.89% |
| 1 year (2024-05-03) | -51.67% |
|---|---|
| 2 years (2023-05-03) | -88.36% |
| 3 years (2022-05-03) | 128.75 |
| 5 years (2020-04-29) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -17.43% |
| Return on equity TTM | -78.91% |
| Profit margin | 0% |
| Book value | $4.32 |
| Market Capitalization | $3.2 million |
TTM: trailing 12 months
We're not expecting Synaptogenix to pay a dividend over the next 12 months.
Synaptogenix's shares were split on a 1:25 basis on 4 April 2024 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Synaptogenix shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Synaptogenix shares which in turn could have impacted Synaptogenix's share price.
Over the last 12 months, Synaptogenix's shares have ranged in value from as little as $1.84 up to $5.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Synaptogenix's is 1.305. This would suggest that Synaptogenix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Synaptogenix, Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. The company was incorporated in 2012 and is headquartered in New York, New York. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Fidelity is best for its extensive tools and resources, while Robinhood is a popular choice for its simple, easy-to-use platform.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .